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ABSTRACT
Introduction A better understanding of the molecular, 
genetic and immunological characteristics of cancer and 
the introduction of new systemic treatment regimens in 
the last decades, has led to better treatment outcomes and 
increased survival rates for patients with previously short 
lived cancers. However, there is no uniform description 
to refer to this growing group of patients with advanced 
cancer who now respond to new systemic treatments 
for longer periods. Furthermore, little is known about the 
unique psychological challenges these patients face, living 
with ongoing uncertainty about the course of their disease 
and life expectancy. The objective of this scoping review 
is to identify the psychological aspects experienced by, 
and the definitions used to refer to patients with advanced 
cancer receiving lifelong systemic treatment.
Methods and analysis This review will be among 
the first to summarise literature on the psychological 
issues in the growing group of advanced cancer patients 
undergoing long- term systemic treatment. Articles will be 
retrieved from six databases (MEDLINE, Embase, Web of 
Science, PsycINFO, CINAHL and the Cochrane Database 
of Systematic Reviews) and reviewed for eligibility by two 
investigators independently. Definitions and psychological 
challenges will be extracted and narratively summarised 
following a descriptive approach. Furthermore, results 
will contribute in providing a uniform definition for this 
patient group, and help to identify knowledge gaps to give 
direction to further research in this field.
Ethics and dissemination No ethical approval is 
required. The results of the scoping review will be 
submitted for publication to a scientific journal and 
presented at relevant conferences.
INTRODUCTION
Recently, there have been major improve-
ments in survival rates for some cancers with 
a previously poor prognosis, as a result of the 
increased understanding of the molecular, 
genetic and immunological basis of cancer 
and the introduction of new systemic treat-
ment regimens. An example is the devel-
opment of immunotherapies, which has 
transformed the treatment paradigm for many 
patients with cancer. In particular, mono-
clonal antibodies targeting the programmed 
cell death 1 receptor (PD-1) and its ligand, 
PD- L1, have exhibited impressive activity and 
have become standard therapy for several 
types of cancer such as melanoma, non- small- 
cell lung cancer and lymphoma.1 Further-
more, identification of several types of cancer 
as mutation driven has facilitated the devel-
opment of therapies such as targeted kinase 
inhibitors, which has revolutionised treat-
ment options and outcomes. For example, 
imatinib mesylate was found to improve the 
recurrence- free survival for advanced unre-
sectable or metastatic gastrointestinal stromal 
tumours (GIST), the most common sarcoma 
of the intestinal tract, as first- choice treat-
ment option.2–4 Sunitinib has been approved 
as the second- line treatment and regorafenib 
as third- line treatment of metastatic GIST, 
providing unresectable or metastatic patients 
a prolonged survival from less than 1 year 
prior to the development of these therapies 
to more than 5 years at the present time.5 6 
However, while studies have mainly focused 
on evaluating new treatments in terms of 
progression- free and overall survival rates, 
Strengths and limitations of this study
 ► This scoping review is a first step to summarising 
knowledge in the unexplored field of psychological 
aspects of living with advanced cancer and receiv-
ing lifelong systemic treatment.
 ► An extensive literature search will be performed 
using six databases with a peer- reviewed search 
strategy according to the scoping review guidelines.
 ► The absence of an existing consensus on the defi-
nition of our target group could have consequences 
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little is known about the psychological, emotional and 
social challenges patients face when living longer with 
advanced cancer and receiving ongoing treatment.7
Existing literature and treatment guidelines document 
the physical and psychological impact of cancer diag-
nosis, treatment and side effects, both in the curative 
and palliative setting. By contrast, patients with advanced 
cancer on lifelong therapy have not yet been well studied, 
though diagnoses of incurable cancer and lifelong treat-
ment with possible side effects can have substantial 
consequences for patients, their families, workplaces and 
healthcare resources in the coming years. These patients 
have very limited or no options for cure and must cope 
long term with a life- limiting illness. Literature suggests 
that uncertainty about the future accounts for a consider-
able emotional burden for patients with cancer and their 
relatives,8–10 but little is known about the psychological 
burden of living with long- term continuing uncertainty. 
While the new medical treatments show promising results, 
it is often unknown whether an individual patient will 
respond to the treatment and if so, how long until progres-
sion of disease occurs. This may lead to feelings of fear, 
anxiety, hopelessness and helplessness.8 9 Furthermore, 
most treatment regimens are accompanied with frequent 
medical procedures including scans, which might induce 
scan- associated distress, anxiety, fear of progression and 
uncertainty, which makes decisions on how to arrange 
extended lifetime even more challenging.11
An important barrier to summarising the literature on 
psychological challenges in patients with advanced cancer 
receiving lifelong treatments is the absence of a unified 
definition of this group. Authors have referred to this 
group as ‘patients with metastatic cancer’,10 ‘patients with 
incurable cancer’,9 12 ‘patients with advanced cancer’,7 13 14 
‘patients with chronic cancer’15 and ‘metastatic cancer 
survivors’.9 Defining this specific patient group might be 
challenging but is an essential step in order to develop 
optimal care models and guidelines and to synthesise the 
available evidence relating to this group of patients.16 
To date, no studies systematically mapped the findings 
on psychological aspects in the group of patients with 
advanced cancer receiving lifelong treatments. There-
fore, in order to fully explore this area, a broad literature 
overviewwould be an adequate first step to gain insight, 
and it might give direction to future research and aid 
healthcare providers to address psychological well- being 
in clinical practice.
Objectives
The overall objective of this scoping review is to identify, 
summarise and synthesise knowledge about psycholog-
ical aspects in patients with advanced cancer receiving 
lifelong treatment. More specifically, this review aims to 
answer the following questions:
 ► What is known about psychological aspects and 
concepts that are relevant for this patient group?
 ► What descriptions or definitions are used to refer to 
this patient group?
 ► What are the knowledge gaps regarding psychological 
aspects in patients with advanced cancer?
METHODS AND ANALYSIS
A scoping review is rigorous like a systematic review, 
however, in contrast to a systematic review it serves the 
purpose of exploring a broader topic by summarising key 
concepts, types of evidence and research gaps, regardless 
of study design and quality.17 The scoping review will be 
conducted following the five stages of the framework of 
Arksey and O'Malley17 and later adaptations of Levac et 
al.18 and The Joanna Briggs Institute19: (1) identifying 
the research questions; (2) identifying eligible studies 
(search terms and inclusion/exclusion criteria); (3) 
study selection; (4) charting the data and (5) collating, 
summarising and reporting the results. The results will be 
reported according to the guideline Preferred Reporting 
Items for Systematic Reviews and Meta- Analysis: exten-
sion for Scoping Reviews (PRISMA- ScR).20
Stage 1: identifying the research questions
The research question was developed and refined through 
an iterative process, leading to the following: ‘What 
has been reported about the psychological aspects in 
patients with advanced cancer receiving life- long systemic 
treatment?’. An exploratory search in PROSPERO, the 
international prospective register of systematic reviews 
of the National Institute for Health Research,21 and the 
Cochrane library, revealed no comprehensive reviews 
addressing a similar research question.
Stage 2: identifying relevant studies
Searches are aimed to include studies that involve adult 
patients (≥18 years of age) with a current diagnosis of 
advanced cancer receiving lifelong systemic treatment 
including targeted therapy, immunotherapy, hormone 
therapy or chemotherapy. Studies on patients receiving 
treatment with curative intent or end- of- life care will 
be excluded. Studies must describe at least one psycho-
logical outcome in this patient population as a primary 
outcome, for instance psychological symptoms, psychi-
atric disorders, emotions, distress, quality of life, coping, 
concepts like uncertainty, hope or optimism, or patients’ 
needs and concerns. Both non- empirical articles (eg, 
expert opinion papers) and empirical quantitative or 
qualitative articles (eg, trials or interview studies) will be 
assessed. Eligible conference abstracts and abstracts of 
non- published papers will only be included on account of 
finding the full text paper.
Project team members identified key free text and 
index terms based on a preliminary search in MEDLINE. 
The MEDLINE strategy was further refined in collabora-
tion with an academic librarian with expertise in system-
atic and scoping review searching, and peer reviewed 
similar to the methods described in the Peer Review of 
Electronic Search Strategies (PRESS) guideline.22 Deci-
sions regarding use of free- text fields, focus of subject 
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completeness and feasibility, as recommended in scoping 
review guidelines.18 23 The MEDLINE strategy (online 
supplemental material 1) was then adjusted to the elec-
tronic databases Embase, CINAHL, PsycINFO, Web 
of Science and the Cochrane Database of Systematic 
Reviews, tailoring vocabulary and syntax for optimal elec-
tronic searching. The search strategy will be limited to 
studies published after 2000, since new systematic treat-
ment options for advanced cancer emerged in the last two 
decades, and will not be limited by language. Additional 
eligible articles will be identified through hand searching 
the reference lists of the final selected articles.
Stage 3: study selection
Results retrieved from all databases will be imported 
into the reference management software EndNote24 and 
duplicate references will be removed using the compre-
hensive stepped procedure described by Bramer et al.25 
The references will then be transferred into Rayyan, a 
web application for systematically reviewing literature, to 
log the screening process and to visualise disagreements 
in screening between researchers.26 Study selection will 
be performed in three steps. First, a manual based on the 
above mentioned inclusion and exclusion criteria will be 
developed. The manual will be pilot tested in a sample 
of 100 references and adapted if necessary. Second, title 
and abstract of all references will be assessed on eligibility 
by two researchers independently. Disagreements will be 
discussed until consensus is reached, and if necessary by 
consulting a third independent researcher. Third, full- 
text articles will be independently reviewed on eligibility 
by two researchers. Disagreements will again be discussed 
to reach consensus on final inclusion. A PRISMA- ScR flow 
chart will be developed to report the whole process of 
selection of articles.20
Stage 4: charting the data
A standardised data extraction form will be developed. 
First, two researchers will independently apply this form 
to a subsample of the included articles (ie, 10%) and 
compare the results in order to ensure consistency in 
data extraction. If necessary, the data extraction form 
will be revised by an iterative process in consultation with 
the research team until consensus is reached. Second, 
complete data extraction will be performed by one 
researcher and verified by a second researcher. Extraction 
results will be discussed at several moments during the 
review process until consensus is reached, if necessary by 
involving a third researcher.
We anticipate to extract the following data: (1) 
author(s); (2) publication year; (3) country; (4) publica-
tion type and/or study design; (5) sample size and patient 
characteristics; (6) reported psychological aspects; (7) 
methods for data collection and analysis; (8) psycholog-
ical measurement instruments; (9) results of reported 
psychological aspects; (10) terminology used to refer 
to ‘advanced cancer patients’; and if applicable (11) 
definition of ‘advanced cancer’. The Standard Quality 
Assessment Criteria for Evaluating Primary Research 
Papers, containing one checklist for qualitative studies 
and one checklist for quantitative studies will be used to 
assess the quality of articles.27
Stage 5: collating, summarising and reporting the results
First, the individual study characteristics will be presented 
in tables, providing an overview of study designs, patient 
populations, reported psychological outcomes, psycho-
logical measurement instrumentsand analysis methods 
that have been used to study the psychological aspects in 
advanced cancer patients. Second, reported psychological 
aspects will be summarised. Findings from the quantita-
tive studies will be narratively summarised. Findings from 
the qualitative studies as reported in the results sections 
will be extracted and synthesised into overarching psycho-
logical themes. We will choose an appropriate qualitative 
synthesis method in accordance with the nature of the 
original papers. Third, an overview of the terminology 
and definitions used to refer to advanced cancer patients 
on lifelong systemic treatment will be given. Elaboration 
on this overview will guide in providing a uniform defi-
nition. The overall synthesis of the available literature 
contributes to the identification of knowledge gaps to 
guide further research in this area.
Patient and public involvement
No patient involved.
ETHICS AND DISSEMINATION
A scoping review does not require ethical approval since 
it synthesises publicly available literature. The results of 
the scoping review will be submitted for publication to a 
scientific journal and presented at relevant conferences.
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